BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 38810179)

  • 1. Discovery and Validation of a 15-Gene Prognostic Signature for Clear Cell Renal Cell Carcinoma.
    Mehra R; Nallandhighal S; Cotta B; Knuth Z; Su F; Kasputis A; Zhang Y; Wang R; Cao X; Udager AM; Dhanasekaran SM; Cieslik MP; Morgan TM; Salami SS
    JCO Precis Oncol; 2024 May; 8():e2300565. PubMed ID: 38810179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature.
    Nallandhighal S; Vince R; Karim R; Groves S; Stangl-Kremser J; Russell C; Hu K; Pham T; Cani AK; Liu CJ; Zaslavsky A; Mehra R; Cieslik M; Morgan TM; Palapattu GS; Udager AM; Salami SS
    Eur Urol Oncol; 2022 Feb; 5(1):92-99. PubMed ID: 34840106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and verification of a nomogram for prediction of recurrence-free survival in clear cell renal cell carcinoma.
    Chen Y; Jiang S; Lu Z; Xue D; Xia L; Lu J; Wang H; Xu L; Li L; Li G
    J Cell Mol Med; 2020 Jan; 24(2):1245-1255. PubMed ID: 31782902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study.
    Wei JH; Feng ZH; Cao Y; Zhao HW; Chen ZH; Liao B; Wang Q; Han H; Zhang J; Xu YZ; Li B; Wu JT; Qu GM; Wang GP; Liu C; Xue W; Liu Q; Lu J; Li CX; Li PX; Zhang ZL; Yao HH; Pan YH; Chen WF; Xie D; Shi L; Gao ZL; Huang YR; Zhou FJ; Wang SG; Liu ZP; Chen W; Luo JH
    Lancet Oncol; 2019 Apr; 20(4):591-600. PubMed ID: 30880070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
    Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
    Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of a gene signature in clear cell renal cell carcinoma.
    Chen L; Luo Y; Wang G; Qian K; Qian G; Wu CL; Dan HC; Wang X; Xiao Y
    J Cell Physiol; 2019 Jul; 234(7):10324-10335. PubMed ID: 30417359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of an individualized DNA repair-related gene signature in localized clear cell renal cell carcinoma.
    Xiong Y; Qi Y; Lin W; Bai Q; Liu L; Guo J
    World J Urol; 2021 Apr; 39(4):1203-1210. PubMed ID: 32458095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A four-gene signature predicts survival in clear-cell renal-cell carcinoma.
    Dai J; Lu Y; Wang J; Yang L; Han Y; Wang Y; Yan D; Ruan Q; Wang S
    Oncotarget; 2016 Dec; 7(50):82712-82726. PubMed ID: 27779101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma.
    Haddad AQ; Luo JH; Krabbe LM; Darwish O; Gayed B; Youssef R; Kapur P; Rakheja D; Lotan Y; Sagalowsky A; Margulis V
    BJU Int; 2017 May; 119(5):741-747. PubMed ID: 28075543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.
    Liu Y; Liu H; Liu W; Zhang W; An H; Xu J
    World J Urol; 2015 Nov; 33(11):1791-9. PubMed ID: 25630622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of UTX expression in patients with clear cell renal cell carcinoma.
    Wang J; Liu L; Xi W; Long Q; Wang Y; Bai Q; Xia Y; Xu J; Guo J
    Urol Oncol; 2016 Aug; 34(8):338.e19-27. PubMed ID: 27106782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a three-miRNA signature as a novel potential prognostic biomarker in patients with clear cell renal cell carcinoma.
    Luo Y; Chen L; Wang G; Xiao Y; Ju L; Wang X
    J Cell Biochem; 2019 Aug; 120(8):13751-13764. PubMed ID: 30957284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
    Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
    Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.
    Hakimi AA; Ostrovnaya I; Jacobsen A; Susztak K; Coleman JA; Russo P; Winer AG; Mano R; Sankin AI; Motzer RJ; Voss MH; Offit K; Purdue M; Pomerantz M; Freedman M; Choueiri TK; Hsieh JJ; Klein RJ
    Cancer; 2016 Feb; 122(3):402-10. PubMed ID: 26505625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a prognostic immune-associated gene signature in clear cell renal cell carcinoma.
    Shen C; Liu J; Wang J; Zhong X; Dong D; Yang X; Wang Y
    Int Immunopharmacol; 2020 Apr; 81():106274. PubMed ID: 32044664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased expression of CTR2 predicts poor prognosis of patients with clear cell renal cell carcinoma.
    Xia Y; Liu L; Long Q; Bai Q; Wang J; Xu J; Guo J
    Urol Oncol; 2016 Jan; 34(1):5.e1-9. PubMed ID: 26411550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
    Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
    Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
    Laba P; Wang J; Zhang J
    BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.
    Brooks SA; Brannon AR; Parker JS; Fisher JC; Sen O; Kattan MW; Hakimi AA; Hsieh JJ; Choueiri TK; Tamboli P; Maranchie JK; Hinds P; Miller CR; Nielsen ME; Rathmell WK
    Eur Urol; 2014 Jul; 66(1):77-84. PubMed ID: 24613583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.